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Abstract
Background: Endothelial dysfunction is one of the earliest vascular manifestations in the pathogen-
esis of cardiovascular disease. Noninvasive, simple, and inexpensive methods of endothelial function 
assessment are therefore needed.
Methods: Microvascular endothelial function was assessed in coronary artery disease (CAD) patients 
by flow mediated skin fluorescence (FMSF), based on measurements of reduced form of nicotinamide 
adenine dinucleotide (NADH) fluorescence intensity during brachial artery occlusion (ischemic re-
sponse [IRmax]) and immediately after occlusion (hyperemic response [HRmax]). Additionally, plasma 
levels of asymmetric dimethylarginine (ADMA) and endothelin-1 (ET-1) were measured to assess the 
association between biochemical markers and microvascular function evaluated in vivo by FMSF. 
Results:  A significant inverse correlation was found between ADMA levels and hyperemic response 
(r = –0.534, p = 0.003), while ET-1 levels were inversely related to the ischemic response (r= –0.575, 
p = 0.001). Both IR and HR were found lowest in patients with advanced CAD and diabetes. When 
the repeatability of the method was tested, the intraclass correlation coefficient for IRmax and HRmax were 
0.985 (p < 0.001) and 0.914 (p < 0.001), respectively. Moreover, in Bland and Altman analysis, both 
variables IRmax and HRmax showed  good agreement in repeated measurements.
Conclusions: In this pilot study, it was demonstrated that NADH fluorescence measured by FMSF 
device in CAD patients was associated with established plasma endothelial markers, and that both 
ischemic and hyperemic response were blunted in patients with advanced disease and diabetes. Fur-
thermore, FMSF device showed excellent repeatability and good agreement for repeated measurements. 
However, further study is warranted to confirm these results in a larger patient cohort. (Cardiol J 2018; 
25, 1: 120–127)
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Introduction
Cardiovascular disease (CVD), and notably 
coronary artery disease (CAD), remains the leading 
cause of mortality in industrialized countries. En-
dothelial dysfunction is one of the earliest vascular 
manifestations of CVD [1]. Actually, the endothe-
lium plays an important role in the maintenance 
of vascular structure, control of vascular tonus, 
homeostasis, and inflammation. Thus, functional 
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and structural integrity of the endothelium is es-
sential for preventing the initiation and progression 
of atherosclerosis [2].
As previously mentioned, endothelium-de-
rived mediators play an essential role in vascular 
homeostasis. Among them, nitric oxide (NO) 
a potent endogenous vasodilator which is released 
in response to shear stress. Therefore, NO is main-
ly responsible for flow-mediated dilatation (FMD). 
Additionally, NO inhibits platelet aggregation and 
controls processes of vascular inflammation. The 
endogenous competitive inhibitor of NO synthase, 
asymmetric dimethylarginine (ADMA), has been 
shown to decrease both the production and bio-
availability of NO. Therefore, elevated plasma con-
centrations of ADMA have been considered to be 
an indicator of endothelial dysfunction and a risk 
factor for CVD [3].
There is a large body of evidence that endothe-
lin-1 (ET-1) plays a crucial role in vascular inflam-
mation and subsequent atherosclerosis progres-
sion. Additionally, ET-1 is a potent vasoconstrictor 
and mitogen produced in response to hypoxia and 
vessel wall stress. It is known to play an important 
role in endothelial dysfunction. Of note, elevated 
plasma levels of ET-1 have been reported in wide 
range of cardiovascular disorders [4].
Taken together, accumulating evidence sug-
gests that endothelial control of vascular tonus is 
mainly regulated by NO and ET-1, which antago-
nize the effects of each other. Both mediators are 
released in response to shear-stress and influence 
endothelium-dependent vasodilatation [5]. 
Most  studies have focused on assessment of 
endothelial function in conduit arteries using the 
FMD technique. However, microvascular dysfunc-
tion may precede endothelial impairment in large 
arteries and clinical manifestations. Convention-
ally, microvascular endothelial function can be stud-
ied using non-invasive laser Doppler techniques or 
more recent laser speckle contrast imaging coupled 
with brachial artery occlusion. Such an approach 
enables the assessment of endothelium-dependent 
hyperemic response [6]. On the other hand, it does 
not provide information regarding the vascular and 
tissue response which occur during ischemia.
Currently however, it is possible to assess the 
changes in tissue biochemistry in vivo using the 
measurements of reduced form of nicotinamide 
adenine dinucleotide (NADH) fluorescence signal 
intensity. Of note, NADH fluorescence has been 
used in vitro as a test for mitochondrial function [7]. 
Additionally, it has been proven that the decrease in 
oxyhemoglobin levels during arterial occlusion is 
associated with an increase in NADH fluorescence 
in human epidermal cells. Indeed, the epidermis is 
particularly sensitive to hypoxia [8]. The newly-
developed flow mediated skin fluorescence (FMSF) 
device enables measurement of the changes in 
cutaneous NADH fluorescence over time in re-
sponse to brachial artery occlusion. In addition 
to endothelium-dependent hyperemic response, 
FMSF allows the assessment of ischemic response 
which may reflect tissue sensitivity to hypoxia [9].
It has recently been shown that the inter-day 
reproducibility of the newly-developed FMSF 
device is excellent both in healthy volunteers and 
CAD patients. Moreover, it was demonstrated that 
both ischemic and hyperemic response differenti-
ated between healthy subjects and patients with 
CAD suggesting microvascular dysfunction in 
those patients [10]. Therefore, given its relatively 
low cost and ease of use, FMSF seems a promising 
tool for the assessment of microvascular endothe-
lial function in CVDs.
Thus, the aim of this pilot study was to inves-
tigate the relationship between FMSF parameters 
and two established plasma endothelial biomark-
ers ADMA and ET-1. Additionally, the aim in this 
research was to assess the repeatability and agree-
ment for repeated measurements by FMSF device. 
Methods
Study population
This study enrolled 28 consecutive patients 
with stable CAD recruited from the cardiology out-
patient clinic. All  participants were over 18 years 
of age and were included between November 2016 
and May 2017. The diagnosis of CAD was based 
on European Society of Cardiology guidelines [11] 
and angiographically confirmed (> 50% stenosis at 
least in 1 major artery based on coronary angiog-
raphy). This study included patients with a history 
of acute coronary syndrome or with prior percuta-
neous coronary intervention. All participants had 
remained in stable condition for at least 3 months 
prior to inclusion to the study and no alterations of 
pharmacotherapy had been introduced over that 
period. Patients with cancer, history of substance 
abuse and/or with respiratory, kidney or hepatic 
failure were excluded from the study.
The study conforms to the principles outlined 
in the Declaration of Helsinki. The study protocol 
was approved in June 2016 by the Independent 
Ethics Committee at the Medical University of 
Gdansk (IRB no. 667). All subjects gave written 
informed consent prior to participation.
www.cardiologyjournal.org 121
Maria Tarnawska et al., Flow mediated skin fluorescence to assess endothelial function
Study design 
This was an open-label, single-center study. 
Blood samples for biochemical measurements were 
collected in the morning, prior to microvascular 
function assessment. Subjects were placed in 
a temperature-controlled room (24 ± 1°C). After 
a 15-min acclimatization period, baseline NADH 
fluorescence intensity was recorded for 3 min on 
the forearm. Then, blood flow in the brachial artery 
was occluded for 3 min by inflating a cuff placed 
on the left upper arm to 50 mm Hg above systolic 
blood pressure. During the occlusion period, the 
NADH fluorescence was continuously measured in 
the same area of the forearm. The cuff was then 
released and the decrease in fluorescence was 
recorded until return to baseline values. 
FMSF measurements
Flow mediated skin fluorescence is a nonin-
vasive optical technique to study microcirculation 
based on measurements of skin fluorescence in-
tensity. FMSF was quantified using AngioTester 
(SN-2016-009M, Angionica, Lodz, Poland). 
Excitation of the forearm with ultraviolet (UV) 
light at 340 nm results in the emission of a NADH 
fluorescence signal from the skin tissue cells. The 
level of NADH fluorescence corresponds to the bal-
ance of mitochondrial oxidation-reduction processes 
occurring in the tissue, reflected by the balance 
between the oxidized form of the coenzyme (NAD+) 
and its reduced form (NADH). Indeed, NADH fluo-
rescence is the strongest component of the fluo-
rescence emitted from human skin. The intensity 
of the signal also changes as a function of time in 
response to blockage and release of blood flow in the 
brachial artery. The emitted fluorescence light of 
NADH at 460 nm is detected by receiver diode and 
corresponds to the activity of microcirculation [9].
The maximal penetration of the exciting light 
(340 nm) is about 0.3 to 0.5 mm, but over 90% of 
the NADH excitation occurs at a depth of 0.1 mm. 
Therefore, a substantial fraction of the exciting light 
is absorbed by the epidermidis. To allow for this, in 
FMSF, the diameter of the probe (detection window) 
is relatively large, 20 mm, which gives approximately 
100 mm3 volume of the investigated tissue [9].
Technical description of FMSF device
The FMSF device consists of three main parts: 
a light source, system of filters, and detector. The UV 
diode emits light at 340 nm wavelength and a small 
amount of blue light to show that the diode is wor- 
king (Marktech Optoelectronics MTE340H21-UV, 
Peak Wavelength 340 nm, Spectral Line Half 
Width 9 nm). Blue light is cut through the band pass 
filter (Hoya U340) which allows the transmission 
of  only UV light at 340 nm and blocks the visible 
light. Then the light beam passes through a quartz 
window, which has excellent transmission to the 
skin (over 90%). 
The emitted fluorescence light of NADH at 
460 nm is detected by the receiver diode (OSI 
Optoelectronics UV-035EQ). There are 2 filters in 
front of the detector which block the possibility of 
reaching the UV detector reflected from the hand 
or  measuring head components. The first filter 
is made of material Thermoset ADC (CR-39®, 
Edmund Optics), the second is an interference 
460 nm filter (Full Width-Half Max FWHM 10 nm, 
Minimum Transmission [%] > 50, Edmund Optics).
Biochemical measurements  
of ADMA and ET-1
Blood samples for the specified biomarkers 
were collected on the day of FMSF examination 
between 8 a.m. and 10 a.m., after at least 8 h of 
fasting. Plasma was obtained and stored at –70°C 
until assaying. Both markers were measured with 
an enzyme-linked immunosorbent assay (ELISA) 
according to manufacturer instructions. ELISA kit 
for measurement of ADMA was purchased from 
BioVendor (Brno, Czech Republic), while ET-1 
concentration was determined using ELISA kit 
from Phoenix Pharmaceuticals Inc. (Burlingame, 
CA, USA).
Data analysis
Data were digitized, stored on a computer, and 
analyzed off-line with signal processing software 
(AngioTester Software, Angionica, Lodz, Poland). 
Two different parameters were measured: the is-
chemic response (IRmax) defined as the ratio (in %) 
relative to baseline (before occlusion) maximal 
increase in NADH fluorescence intensity observed 
during cuff occlusion and the hyperemic response 
(HRmax) expressed (in %) as relative to baseline 
(after occlusion) maximal decrease in NADH 
fluorescence intensity after cuff release (Fig. 1).
Statistical analysis
Quantitative data are expressed as the mean 
and standard deviation. The Pearson correlation 
test was used to assess the relationship between 
FMSF variables and endothelial biochemical mark-
ers. To evaluate the reliability of repeated meas-
urements, intraclass correlation coefficients (ICC) 
were calculated and the Bland-Altman plots were 
applied. ICC values of < 0.40, 0.40–0.75 and 
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> 0.75 represent poor, fair to good and excellent 
agreement, respectively. Differences between 
mean values in independent groups were examined 
by parametric Welch t-test and complemented by 
nonparametric Mann-Whitney U test. Normality 
assumption of data set was checked by the Shapiro-
Wilk test. A p-value of < 0.05 was considered 
statistically significant. All statistical analyses were 
performed using Statistica version 12.0 (StatSoft, 
Tulsa, OK, USA).
Results
Patients characteristics
In this pilot study, stable CAD patients were 
enrolled. The demographic and clinical characteris-
tics of the study group are summarized in Table 1. 
All participants completed the protocol.
Plasma biomarkers and FMSF parameters
Mean plasma levels of ET-1 and ADMA were 
0.3 ± 0.1 ng/mL, and 0.64 ± 0.1 μmol/L, respec-
tively. Mean values of IRmax and HRmax were 8.2 ± 
± 4.6 and 11.8 ± 5.0, respectively. In a subset of pa-
tients with left ventricular (LV) dysfunction when 
compared to patients with preserved LV function, 
a trend was noted for lower IRmax (6.6 ± 3.2 vs. 9.6 ± 
± 5.2, respectively, p = 0.075) and reduced HRmax 
(10.9 ± 6.3 vs. 12.5 ± 3.4, respectively, p = 0.181). 
Table 1. Clinical characteristics of coronary  
artery disease patients (n = 28).
Male/female [n/n] 20/8
Age [years] 64.4 ± 7.5
Body mass index [kg/m2] 28.5 ± 4.8
Systolic blood pressure [mm Hg] 141.3 ± 16.8
Diastolic blood pressure [mm Hg] 80.4 ± 9.9
Pulse wave velocity [m/s] 9.3 ± 2.2
Heart rate [bpm] 66.3 ± 7.4
Hypertension 25 (90%)
Diabetes mellitus 15 (53%)
Chronic heart failure 13 (47%)
Left ventricular ejection fraction [%] 51.7 ± 9.7
B-type natriuretic peptide [pg/mL] 106.7 ± 188.1
Creatinine [mg/dL] 0.98 ± 0.2
Total cholesterol [mg/dL] 157 ± 32
LDL cholesterol [mg/dL] 88 ± 28
HDL cholesterol [mg/dL] 46 ± 10 
HDL — high density lipoprotein; LDL — low density lipoprotein
Figure 1. The exemplary image of NADH fluorescence trace in response to blockage and release of blood flow in the 
brachial artery. The ischemic response (IRmax) is relative to baseline maximal increase in NADH fluorescence intensity 
observed during cuff occlusion and the hyperemic response (HRmax) is relative to maximal decrease in NADH fluores-
cence intensity after cuff release.
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Similar trends were noted in the diabetic vs. non-
diabetic patients for lower IRmax (7.1 ± 4.9 vs. 9.5 
vs. 3.8, respectively, p = 0.087) and for reduced 
HRmax (10.3 ± 4.3 vs. 13.5 ± 5.2, respectively, 
p < 0.05). In patients with LV dysfunction and 
diabetes, as compared with diabetic CAD patients 
with preserved LV function, both IRmax (4.2 ± 1.7 
vs. 8.6 ± 3.5, respectively, p < 0.05) and HRmax 
(5.6 ± 1.7 vs. 12.6 ± 3.1, respectively, p < 0.001) 
were markedly reduced.
Correlation analyses
As shown in Figure 2, in CAD patients, a sig-
nificant inverse correlation between plasma ADMA 
levels and hyperemic response was observed 
(r = –0.534, p = 0.003). In contrast, no such re-
lationships were found for ADMA concentrations 
and ischemic response (r = 0.028, p = 0.889). Fur-
thermore, ET-1 levels were strongly and inversely 
associated with the ischemic response (r = –0.575, 
p = 0.001) (Fig. 3). Whereas, no correlation was 
observed between ET-1 and hyperemic response 
(r = 0.048, p = 0.810).
Repeatability of FMSF measurements
As presented in the Figure 4A and 4B, the 
intraclass correlation coefficient for repeated 
measurements was 0.985 for IRmax (p < 0.001) and 
for HRmax was 0.914 (p < 0.001). Bland and Altman 
plots for repeated IRmax and HRmax measurements 
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Figure 2. Correlation analysis between asymmetric 
dimethylarginine (ADMA) plasma levels and hyperemic 
response (HRmax) in coronary artery disease subjects.
Figure 3. Correlation analysis between endothelin-1 (ET-1) 
plasma levels and ischemic response (IRmax) in coronary 
artery disease subjects.
Figure 4. Repeatability of ischemic response (IRmax) and hyperemic response (HRmax). Correlation analysis across consecutive 
measurements of IRmax (A) and HRmax (B). The intraclass correlation coefficient (ICC) was slightly better for IRmax than HRmax.
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are presented in Figure 5. Although, both vari-
ables IRmax and HRmax showed a good agreement 
for repeated measurements, the bias (–0.1600) and 
limits of agreement (–1.854; 1.534) for repeated 
IRmax (Fig. 5A) were slightly better than the bias 
(–0.2467) and limits of agreement (–3.131; 2.638) 
for repeated HRmax (Fig. 5B).
Discussion 
The key finding of this pilot study is that both 
FMSF indices, IRmax and HRmax, significantly inverse-
ly correlated with ET-1 and ADMA, respectively. 
ADMA, the endogenous inhibitor of NO synthase, is 
inversely related to hyperemic response measured 
by FMSF. As an endothelium-derived NO is released 
in response to the increase of sheer stress, an im-
portant regulator of FMD. In the current study, CAD 
patients with high ADMA plasma levels presented 
low values of hyperemic response, which is most 
likely due to the reduced NO bioavailability. Such 
data are consistent with a previously published re-
port which showed that elevated ADMA levels are 
associated with impaired hyperemic response in es-
sential hypertension [12]. Similarly, in another study 
using FMD, endothelium-dependent vasodilatation 
was inversely related to ADMA concentrations in 
patients with hypercholesterolemia [13]. Indeed, 
a large body of evidence suggests ADMA to be as-
sociated with endothelial dysfunction. Additionally, 
an elevated plasma level of ADMA may predict 
adverse cardiovascular events in patients with CAD 
and chronic heart failure [14].
Additionally, this pilot study showed, for the 
first time, that plasma ET-1 levels were strongly 
and inversely associated with the ischemic re-
Figure 5. Bland and Altman plots for consecutive measurements of ischemic response (IRmax) (A) and hyperemic re-
sponse (HRmax) (B). Both variables IRmax and HRmax showed a good agreement for repeated measurements; CL — confi-
dence limits; SD — standard deviation.
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sponse as measured by the novel FMSF device. 
With the FMSF technique, lack of oxygen during 
arterial occlusion is associated with an increase in 
NADH fluorescence intensity. Indeed, NADH is 
a major mitochondrial component which plays a key 
role in cellular energy metabolism [8]. Therefore, 
the measurement of ischemic response provides 
insight into mitochondrial function, and its am-
plitude may reflect tissue sensitivity to hypoxia. 
Importantly, accumulating evidence suggests that 
mitochondria are probably the most important 
sensors of oxygen level in the cells. Therefore, 
mitochondrial dysfunction may lead to a decrease 
in the oxygen consumption rate. In line with the 
present results, it has been previously shown in 
an animal model that mitochondrial dysfunction 
increases expression of ET-1 [15]. 
Additionally, there is compelling evidence for 
a link between the pathogenesis of CVD and increased 
mitochondrial dysfunction [16]. Therefore, the possi-
bility of monitoring the oxygen-dependent processes 
in the mitochondria is crucial in understanding the 
pathophysiology of CVDs such as CAD [17]. In the 
presented pilot study, mitochondrial function was 
evaluated in vivo in humans by measuring an ischemic 
response via NADH fluorescence recording. It was 
shown that CAD patients with high ET-1 plasma 
levels presented low values of ischemic response 
suggesting their low sensitivity to intermittent 
hypoxia. It has been reported that plasma levels of 
ET-1 are elevated in patients with atherosclerosis. 
Indeed, ET-1 is a potent vasoconstrictor produced in 
response to hypoxia and high levels of ET-1 which 
have been also been associated with microvascular 
dysfunction [4]. Additionally, it was demonstrated 
that active vasoconstriction of large arteries during 
reduced blood flow is mediated by endothelin recep-
tor activation and can exacerbate ischemia [5]. Thus, 
in patients with CAD immediate response to hypoxia 
seems blunted, which results in limited increase 
of NADH fluorescence intensity leading to lower 
ischemic response in FMSF examination. 
While analyzing these preliminary results, it 
should be noticed that there are several important 
factors which could influence FMSF ischemic 
and hyperemic responses. In this pilot study, 
a trend was found towards reduced IRmax and HRmax 
parameters in type 2 diabetes compared to those 
without diabetes. Furthermore, the IRmax and HRmax 
parameters were also blunted in CAD patients with 
LV dysfunction compared to CAD patients with 
preserved LV function. Moreover, the IRmax and 
HRmax were markedly reduced in individuals with 
LV dysfunction combined with diabetes suggesting 
that microvascular endothelial function is impaired 
due to advanced diseases and comorbidities known 
to affect the endothelium.
Lastly, as FSMF device is a new measurement 
tool, its performance was also evaluated. As previ-
ously demonstrated, the inter-day reproducibility 
of the FMSF device is excellent [10]. In this study, 
an assessment was made of inter-observer agree-
ment using the same device in the same subject 
under identical conditions. Using Bland and Altman 
plots, it was shown that both ischemic and hyper-
emic responses presented high concordance for 
repeated measurements, with slightly better agree-
ment for ischemic response. Similarly, the ICC 
values suggested slightly better inter-observer 
agreement for ischemic response than hyperemic 
response values. 
As FMSF technique is noninvasive, reproduc-
ibility  is  easy to perform and can be particularly 
useful in clinical trials on endothelial function. It 
may also be a promising tool for the evaluation of 
novel cardiovascular drugs.
Limitations of the study
This study has several limitations. First, the 
study group was relatively small, but sufficient 
from a statistical point of view for reaching the 
conclusions. Thus, further research with larger 
sample sizes is strongly needed. Secondly, results 
were not confirmed by any other technique meas-
uring microvascular endothelial function. While all 
microvascular techniques quantify blood flow, the 
FMSF device,  according to available literature, 
is the first method to measure metabolic changes 
which directly depend on local perfusion. Further 
mechanistic studies are needed to explain the 
regulation mechanisms of these changes. 
Conclusions 
In conclusion, this pilot study demonstrated 
that in patients with CAD, NADH fluorescence 
measured by the FMSF device is associated with 
established plasma endothelial markers and that 
both ischemic and hyperemic response were blunt-
ed in patients with advanced disease and diabetes. 
This suggests that FMSF is a useful tool for the 
assessment of endothelial function. Furthermore, 
FMSF device showed excellent repeatability and 
good agreement for repeated measurements. How-
ever, further study is warranted to confirm these 
results in a larger patient cohort.
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